US Vaccine Program Picks Up Momentum, Daily Cases Drop
22 Mar 2021 · 3rd Party Analysis
- The US Vaccine Program on track to vaccinate 75% of adults buy midsummer
- American vaccine makers significantly increase monthly output
The US Vaccine Program has boosted up this past month. On Friday, Joe Biden celebrated the fulfillment of his target to give the shot to at least 100 million Americans in his first 100 days in office. It took the President 58 days to reach that mark which placed the US ahead in the vaccination campaign around the world.
Vaccine makers in the US have massively ramped up production this month. Pfizer, Moderna, and Johnson & Johnson have accelerated efforts and scaled up their production lines. The improvements in the vaccination program across the states are raising hopes that the broader economy will soon reopen. With businesses and establishments returning to their daily operations, boosting the economic recovery. In addition to the production upgrade, administering the vaccine has also seen a strong increase. On a daily average, 2.5 million people receive the vaccine, up from 500,000 in January. The positive development on the vaccine front has been keeping the daily number of new cases below 60,000 for the large part of March with only 6 days in which cases climbed above 60,000. In comparison, at the peak of the second wave of the pandemic in January this year, the registered cases daily in the US reached over 250,000 and even above 300,000 in some days.
According to the CDC Covid data tracker, the US has so far delivered 156 million vaccine doses and 124 million have been administered to the population. The country has given 37.6 shots per 100 residents, using the three authorized vaccines, Pfizer, Moderna, and Johnson & Johnson. The three vaccine makers are expected to reach a total monthly output of over 130 million doses for March, a significant improvement compared with February’s 48 million doses.
Vaccine Production Ramps Up
According to research by Morgan Stanley, over 75% of the American population should be vaccinated by midsummer. With the current vaccination rate, authorities expect to fully vaccinate 76 million Americans in March, 75 million in April, and another 89 million in May. US health experts are also working on shots for adolescents as the current vaccines are not authorized for people younger than 16 years of age.
Moderna is set to be able to produce at least 50 million doses per month by June, according to Juan Andres, chief technical operation and quality officer at the pharmaceutical company. It took Moderna three months to make the first 20 million doses after it received the green light from the government last year. Now, the drugmaker has a monthly output of 40 million doses having added new equipment, more floor space, and a lot more staff.
Pfizer has also stepped up efforts and has increased its monthly production to at least 50 million, double its output in early February. And Johnson & Johnson, in partnership with Merck, has boosted the production of its vaccine authorized in late February, and now it expects to deliver a total of 20 million doses ready for use in the US by the end of March.